Table 3 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Year: 2025
Type: other
Abstract: Most common AEs (all-cause) ≥10% overall patients (safety population).
Authors: Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan, Naamit K. Gerber, Jason J. Luke, John P. Gibbs, Richard C. Gregory, Kwok-Kin Wong, Jiehui Deng, Samanthi A. Perera, Kai Ding, Emily R. Roberts, Allison Berger, Camilla L. Christensen, Erica Xin Tong, Angel E. Maldonado López, Vicky A. Appleman, E. Jane Leonard, Alexander Parent, Yu-Chung Huang, Camden Bay, Cong Li, Neil Lineberry, Jeffrey Raizer, Daniel J. Olson, Steven J. Chmura
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7117652544